Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

GLORIA Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Rekrutierend

NCT-Nummer:
NCT04121455

Studienbeginn:
September 2019

Letztes Update:
03.03.2021

Wirkstoff:
Olaptesed pegol

Indikation (Clinical Trials):
Glioblastoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
NOXXON Pharma AG

Collaborator:
-

Kontakt

Diana Beyer, Dr.
Kontakt:
Phone: +49 30 72 62 47
Phone (ext.): 100
E-Mail: clinicaltrialdisclosuredesk@noxxon.com
» Kontaktdaten anzeigen

Studienlocations (3 von 3)

Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie
Bonn
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Klinik für Neurologie
Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Klinik für Strahlentherapie und Radioonkologie
Mannheim
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps

Studien-Informationen

Brief Summary:

The purpose of this study is to obtain first, exploratory information on the safety and

efficacy of olaptesed pegol in combination with radiation therapy in patients with newly

diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection

(biopsy only) or after incomplete tumor resection.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Written informed consent

2. Age ≥18 years

3. Patient agreement to diagnostic and scientific work-up of glioblastoma tissue obtained

during the preceding surgery or biopsy

4. Patient agrees to subcutaneous port implantation

5. Newly diagnosed, histologically confirmed, supratentorial WHO grade IV glioblastoma

6. Status post biopsy or incomplete resection

7. Unmethylated MGMT promoter status

8. Maximum Eastern Cooperative Oncology Group (ECOG) score 2

9. Estimated minimum life expectancy 3 months

10. Stable or decreasing dose of corticosteroids during the week prior to inclusion

11. The following laboratory parameters should be within the ranges specified:

- Total bilirubin ≤ 1.5 x upper limit normal (ULN)

- Creatinine ≤ 1.5 x ULN or glomerular filtration rate ≥ 60 mL/min/1.73m²

- ALT (alanine transaminase) ≤ 3 x ULN

- AST (aspartate transaminase) ≤ 3 x ULN

12. Female patients of child-bearing potential must have a negative serum pregnancy test

within 21 days prior to enrollment and agree to use a highly effective method of birth

control (failure rate less than 1% per year when used consistently and correctly such

as contraceptive implants, vaginal rings, sterilization, or sexual abstinence)" during

and for 3 months following last dose of drug (more frequent pregnancy tests may be

conducted if required per local regulations)

13. Male patients must use an effective barrier method of contraception during study and

for 3 months following the last dose if sexually active with a FCBP

Exclusion Criteria:

1. Inability to understand and collaborate throughout the study or inability or

unwillingness to comply with study requirements

2. Participation in any clinical research study with administration of an investigational

drug or therapy within 30 days from screening visit or observation period of competing

studies

3. Contra-indication or known hypersensitivity to MRI contrast agents, olaptesed pegol or

polyethylene glycol

4. Cytostatic therapy (chemotherapy) within the past 5 years

5. History of other cancers (except for adequately treated basal or squamous cell skin

cancer, in situ cervical cancer, or other cancer from which the patient was

disease-free for ≥ 5 years)

6. Clinically significant or uncontrolled cardiovascular disease

7. Prior radiotherapy to the head

8. Any other previous or concomitant experimental glioblastoma treatments

9. Placement of Gliadel® wafer, seeds, or ferromagnetic nanoparticles

10. Pregnancy or lactation

11. Uncontrolled intercurrent illness; patients must be free of any clinically relevant

disease (other than glioma) that would, in the treating investigator's opinion,

interfere with the conduct of the study or study evaluations

12. Treatment not initiated within 6 weeks after first biopsy or surgery of glioblastoma

13. Prior enrolment into this study

Studien-Rationale

Primary outcome:

1. Safety - Number of patients with treatment-related adverse events as assessed by CTCAE (Time Frame - 26 weeks):
Number of patients with treatment-related adverse events as assessed by CTCAE



Secondary outcome:

1. Efficacy - progression free survival at 6 months (PFS-6) (Time Frame - 6 months):
Progression free survival at 6 months (PFS-6) in %

2. Efficacy - Median progression-free survival (mPFS) (Time Frame - 24 months):
Median progression-free survival (mPFS) in months

3. Efficacy - Median overall survival (mOS) (Time Frame - 24 months):
Median overall survival (mOS) in months

4. Efficacy - Tumor vascularization as per vascular MRI (Time Frame - 24 months):
Changes from baseline in tumor vascularization over time as %cerebral blood volume

5. Plasma level of olaptesed pegol (Time Frame - 26 weeks):
concentration of olaptesed pegol in plasma in µmol/L

6. Quality of Life (QoL) EORTC QLQ-C30 Module (Time Frame - 24 months):
Quality of Life measures are recorded according to EORTC QLQ30 module, which is validated for cancer patients in general and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment.

7. Quality of Life (QoL) EORTC QLQ BN-20 Module (Time Frame - 24 months):
Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment.

8. Neurologic functions as measured by the NANO scale (Time Frame - 24 months):
Change from baseline in neurologic performance scores by Neurologic Assessment in Neuro-Oncology (NANO) scale as an objective and quantifiable metric of neurologic function evaluable during a routine office examination. The NANO Scale evaluates 9 major domains of neurologic function, with each domain being scored on a range from 0 to 2 or 3.

Studien-Arme

  • Experimental: 200 mg Olaptesed pegol + Radiotherapy
    olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
  • Experimental: 400 mg Olaptesed pegol + Radiotherapy
    olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
  • Experimental: 600 mg Olaptesed pegol + Radiotherapy
    olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6

Geprüfte Regime

  • Olaptesed pegol:
    Olaptesed pegol continuous administration for 26 weeks
  • Radiotherapy:
    Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Bayerisches Bürgertelefon hilft beim Kampf gegen Krebs

Bayerisches Bürgertelefon hilft beim Kampf gegen Krebs
©Photographee.eu - stock.adobe.com

Seit Anfang Juli können sich Menschen unter der Nummer 0800 85 100 80 kostenlos zum Thema Krebs informieren. Das Bayerische Zentrum für Krebsforschung (BZKF) bündelt die Kompetenzen der 6 bayerischen Universitätsklinika und bietet dabei zusätzlich einen kostenlosen Telefon-Service an. Gerade jetzt in Zeiten von Corona, in denen viele Menschen nicht unbedingt zum Arzt gehen möchten, hilft das BürgerTelefonKrebs offene Fragen zu beantworten. 

Rudern gegen Krebs

Rudern gegen Krebs
© Universitätsklinikum Ulm

Die dritte Benefiz-Regatta Rudern gegen Krebs auf der Donau unter der Schirmherrschaft des Ulmer Oberbürgermeisters Gunter Czisch startet am Sonntag, 26. Juni 2016. Initiator und Veranstalter ist die Stiftung Leben mit Krebs in bewährter Kooperation mit der Sektion Sport- und Rehabilitationsmedizin am Universitätsklinikum Ulm und dem Ulmer Ruderclub Donau e. V.. Bereits am 21. April starten die Patientinnen und Patienten offiziell mit dem Vorbereitungstraining für die...

Krebstherapie-Nebenwirkungen wirksam bekämpfen, Patienten unterstützen – Bundesweit gültige Leitlinie verabschiedet

Krebstherapie-Nebenwirkungen wirksam bekämpfen, Patienten unterstützen – Bundesweit gültige Leitlinie verabschiedet
© vitanovski / Fotolia.com

Etwa eine halbe Millionen Menschen erkranken jedes Jahr in Deutschland an Krebs. Für viele ist die Behandlung mit erheblichen Nebenwirkungen verbunden, die die Lebensqualität der Patienten deutlich beeinträchtigen. Doch längst gibt es wirksame Therapien, um Nebenwirkungen wie Übelkeit und Erbrechen besser in den Griff zu bekommen. Die so genannten unterstützenden oder Supportiven Therapien haben in den vergangenen Jahren eine enorme Entwicklung genommen.

Der lange Weg bis zur Zulassung eines Arzneimittels

Die Zulassung eines neuen Arzneimittels und die Erweiterung der Indikation eines bereits zugelassenen Arzneimittels sind streng geregelt. Die europäische oder deutsche Zulassungsbehörde fordert den Nachweis von Wirksamkeit und Unbedenklichkeit, wofür das Arzneimittel verschiedene Phasen der klinischen Prüfung durchlaufen muss. Wie die Arzneimittelprüfung durchzuführen ist, legt das Arzneimittelgesetz (AMG) von 1976 fest, das zuletzt durch die 15. Novelle von...